Table 1. Prevalence of antiphospholipid antibodies in serum from patients with COVID-19 (n = 172).
The manufacturer’s cutoff: aCL IgG, IgM, IgA = 20 IgG, IgM, IgA phospholipid units; aβ2GPI IgG, IgM, IgA = 20 standard IgG, IgM, IgA units; aPS/PT IgG, IgM = 30 IgG, IgM phosphatidylserine units; aPL antibody, antiphospholipid autoantibodies; aCL, anticardiolipin antibodies; aβ2GPI, anti–β2 glycoprotein I antibodies; aPS/PT, anti-phosphatidylserine/prothrombin antibodies.
| aPL antibody |
Number of positive (manufacturer’s cutoff) |
% |
Number of positive (titer ≥40 units) |
% |
| aCL IgG | 8 | 4.7 | 2 | 1.2 |
| aCL IgM | 39 | 23 | 13 | 7.6 |
| aCL IgA | 6 | 3.5 | 1 | 0.58 |
| aβ2GPI IgG | 5 | 2.9 | 3 | 1.7 |
| aβ2GPI IgM | 9 | 5.2 | 7 | 4.1 |
| aβ2GPI IgA | 7 | 4.1 | 3 | 1.7 |
| aPS/PT IgG | 42 | 24 | 21 | 12 |
| aPS/PT IgM | 31 | 18 | 21 | 12 |
| Any positive aPL | 89 | 52 | 52 | 30 |